Genmab achieves milestone with Amgen license agreement by delivering an antibody

18-Sep-2003

Copenhagen, Denmark - Genmab A/S announced today that it has achieved a milestone in its license agreement with Amgen by delivering an antibody that targets the IL15 receptor.

Under the terms of the agreement, Genmab will receive a milestone payment of USD 500,000.

"We are pleased to reach a milestone in our agreement with Amgen," said Lisa N. Drakeman, Ph. D. Chief Executive Officer of Genmab.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...